No abstract available
MeSH terms
-
Angiogenesis Inhibitors / economics*
-
Angiogenesis Inhibitors / therapeutic use
-
Antibodies, Monoclonal, Humanized / economics
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Bevacizumab
-
Centers for Medicare and Medicaid Services, U.S. / economics
-
Cost Control
-
Drug Approval
-
Drug Costs*
-
Drug Industry / economics
-
Humans
-
Macular Degeneration / drug therapy*
-
Medicare / economics*
-
Off-Label Use*
-
Ranibizumab
-
Receptors, Vascular Endothelial Growth Factor / economics
-
Receptors, Vascular Endothelial Growth Factor / therapeutic use
-
Recombinant Fusion Proteins / economics
-
Recombinant Fusion Proteins / therapeutic use
-
United States
-
United States Food and Drug Administration
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Recombinant Fusion Proteins
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
aflibercept
-
Bevacizumab
-
Receptors, Vascular Endothelial Growth Factor
-
Ranibizumab